

Translational research in solid tumours

DESCRIPTION OF THE GROUP

The Research Group on Translational Research in solid tumours aims to develop new therapeutic interventions to improve the diagnosis and prognosis of patients suffering from cancer related to the digestive system, mainly based on the identification of molecular biomarkers such as circulating tumour DNA (ctDNA), microRNAs and DNA modifications.

We also conduct clinical trials in order to:

- validate new drugs or reuse others,
- demonstrate the predictive value of biomarkers and,
- determine the recommended dose for the treatment.

At the level of laboratory research, we studied mechanisms of resistance to treatments and also sought new biomarkers in liquid biopsies (ctDNA, microRNAs) for early diagnosis, monitoring and prediction of therapeutic effects in patients with gastrointestinal neoplasms.

Our group is led by Prof. Andrés Cervantes, Head of the Hospital Clínico Universitario Oncology Service, permanent senior lecturer in

the Faculty of Medicine at the University of Valencia and director of the INCLIVA Biomedical Research Institute.

MARKET APPLICATION SECTORS

Pharmaceutical and biotechnological industry in the field of oncology.

Clinical trials and identification of biomarkers for diagnosis, prognosis and prediction of therapy response in cancer related to the digestive system.

GROUP RESOURCES

Research oncology laboratories with about 90m² in three fully equipped laboratories. We have all the medium size instrumentation required for the molecular and genetic experiments. We have access to HiScan and MiSeq Next Generation Sequencers (Illumina), Nanostring equipment and ddPCR, among other equipment.

COLABORATION SOUGHT

Contract research, collaborations for international grants with other academic partners and companies.

CONTACT

INCLIVA Innovation Unit
uai@incliva.es